CD8A and neoplasm: According to data reported by L. Bonanno et al., PD-L1 was expressed on tumor cells and tumor-infiltrating immune cells in 25% and 40% of SCLC cases, respectively, and CD8+ TILs were present in 59% of SCLC samples (32).